NYSE · BMYHealthcarePharmaceuticals

Bristol-Myers Squibb financials

$63.88+1.62%
Close Sep 28, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
FY17
Dec 31
FY16
Dec 31
Revenue$48.19B$48.30B$45.01B$46.16B$46.38B$42.52B$26.14B$22.56B$20.78B$19.43B
Gross profit$34.26B$34.33B$34.31B$36.02B$36.45B$30.75B$18.07B$16.09B$14.76B$14.46B
Gross margin71.1%71.1%76.2%78.0%78.6%72.3%69.1%71.3%71.1%74.4%
Operating income$10.00B-$7.49B$7.28B$8.29B$7.38B-$9.19B$5.91B$5.11B$3.45B$4.47B
Net income$7.05B-$8.95B$8.03B$6.33B$6.99B-$9.02B$3.44B$4.92B$1.01B$4.46B
Net margin14.6%−18.5%17.8%13.7%15.1%−21.2%13.2%21.8%4.8%22.9%
Diluted EPS$3.46$-4.41$3.86$2.95$3.12$-3.99$2.01$3.01$0.61$2.65
EBITDA$14.01B$2.11B$17.04B$18.57B$18.06B$1.20B$7.66B$5.75B$4.24B$4.85B
Operating cash flow$14.16B$15.19B$13.86B$13.07B$16.21B$14.05B$8.21B$7.07B$5.28B$3.06B
Free cash flow$12.85B$13.94B$12.65B$11.95B$15.23B$13.30B$7.37B$6.12B$4.22B$1.84B
Diluted shares2,039.0M2,027.0M2,078.0M2,146.0M2,245.0M2,258.0M1,712.0M1,637.0M1,652.0M1,680.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$10.21B$10.35B$11.46B$9.12B$13.98B$14.55B
Short-term investments$464.0M$513.0M$816.0M$130.0M$2.99B$1.28B
Total debt$45.11B$49.65B$39.77B$39.32B$44.55B$50.68B
Total assets$90.04B$92.60B$95.16B$96.82B$109.31B$118.48B
Total liabilities$71.53B$76.22B$65.67B$65.70B$73.31B$80.60B
Shareholders' equity$18.51B$16.39B$29.48B$31.12B$36.01B$37.88B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology